A single-arm, phase 2 study evaluating the efficacy and safety of combination of lenalidomide and R-ICE in patients of relapsed/refractory non-GCB subtype DLBCL previously treated with R-CHOP

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800016724

Enrollment

Unknown

Registered

2018-06-20

Start date

2018-07-01

Completion date

Unknown

Last updated

2018-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diffuse large B cell lymphoma

Interventions

Case series:combination of RICE and lenalidomide

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. pathology confirmed the diagnosis as DLBCL with non-GCB subtype; 2. previously treated with RCHOP or RCHOP-like regimens; 3. survival time predicted to be longer than 3 months; 4. Aged 18-65 years old; 5. ECOG=0-2; 6. adequate bone marrow, liver, kidney and heart function; 7. ICF given by subjects.

Exclusion criteria

Exclusion criteria: 1. with CNS involvment,or with other malignancies; 2. poor ECOG performance status; 3. pregnancy or lactating women; 4. refuse to accept birth-control methods; 5. hypersensitivity to study drugs; 6. active infection; 7. ICF not given.

Design outcomes

Primary

Measure	Time frame
overall response rate;	—

Secondary

Measure	Time frame
complete remission rate;progression free survival;overall survival;safety;	—

Countries

China

Contacts

Public ContactWang Liang

ZhuJiang Hospital of Southern Medical University

wangliang1234@smu.edu.cn+86 15013009093

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026